Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options
the ONA take:
According to a new study published today in the journal Nature Genetics, researchers from various sites around the world have found that the majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling. Increased signaling in this pathway results in the progression of neuroblastoma.
"Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma," said senior author John M. Maris, M.D., a pediatric oncologist at The Children's Hospital of Philadelphia.
A class of drugs known as MEK inhibitors have demonstrated activity against this signaling pathway, suggesting that MEK inhibitors may benefit relapsed patients who possess mutations on the RAS-MAPK pathway.
Neuroblastoma is a solid tumor of the peripheral system that often grows in the chest or abdomen. It is the most common type of cancer in infants and is known for a high mortality rate in children. Most patients initially respond to chemotherapy, but many relapse and die from the disease.
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|